Group 1 - GH Research PLC has announced a public offering of 10,000,000 ordinary shares at a price of $15.00 per share, aiming for total gross proceeds of approximately $150 million [1] - The offering is expected to close on February 6, 2025, subject to customary closing conditions [1] - GH Research PLC has granted underwriters a 30-day option to purchase an additional 1,500,000 ordinary shares at the public offering price [1] Group 2 - Cantor, Stifel, and RBC Capital Markets are acting as joint book-running managers for the offering, while Canaccord Genuity and Citizens JMP are co-lead managers [2] Group 3 - GH Research PLC is a clinical-stage biopharmaceutical company focused on developing treatments for depression, specifically targeting treatment-resistant depression (TRD) with its proprietary mebufotenin therapies [7]

Company Overview - GH Research PLC is a clinical-stage biopharmaceutical company focused on developing transformative treatments for depression, specifically targeting treatment-resistant depression (TRD) with its proprietary mebufotenin therapies [7]. Offering Details - GH Research PLC has announced a public offering of $150 million of ordinary shares in the United States, with an option for underwriters to purchase an additional $22.5 million of shares [1]. - The offering is subject to market conditions and other factors, with no assurance on the completion or terms of the offering [1]. Underwriters - The joint book-running managers for the offering are Cantor, Stifel, and RBC Capital Markets, with Canaccord Genuity and Citizens JMP acting as co-lead managers [2]. Regulatory Information - A registration statement for the securities was filed with the U.S. Securities and Exchange Commission (SEC) and declared effective on March 17, 2023 [3]. - The offering will be conducted through a prospectus supplement and an accompanying prospectus, which will be available free of charge on the SEC's website [3]. Investor Communication - The announcement specifies that it does not constitute an offer to sell or solicit an offer to buy securities in jurisdictions where such actions would be unlawful [4]. - In the EEA and the UK, the offering is directed only at qualified investors with professional experience in investment matters [5][6].

GH Research (GHRS) Update / Briefing February 03, 2025 08:00 AM ET Company Participants Velichka (Villy) Valcheva - CEOPaul Matteis - Managing Director, Head of Therapeutics ResearchSumant Kulkarni - Managing DirectorJason Butler - Managing Director & Biotechnology Equity ResearchPatrick Trucchio - Managing Director Conference Call Participants Ritu Baral - MD & Senior Biotechnology AnalystElemer Piros - Senior Biotechnology AnalystAthena Chin - Biotechnology Equity Research Analyst Velichka (Villy) Valchev ...

Primary endpoint met, GH001 led to an ultra-rapid anti-depressant effect with a significant placebo-adjusted MADRS reduction from baseline of -15.5 on Day 8 (p<0.0001)The majority of the patients treated with GH001 achieved remission with a 57.5% remission rate on Day 8 compared with 0% in the placebo group (p<0.0001)All other secondary endpoints were met with clinically and statistically significant improvements on Day 8, compared with placeboDuring the double-blind part, GH001 was well tolerated and no se ...

DUBLIN, Jan. 31, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced that it will host a conference call and live webcast on Monday, February 3, 2025, at 8.00 a.m. EST to provide an update on data from the randomized, double-blind, placebo-controlled Phase 2b trial of GH001 in treatment-resistant depression (TRD). To access the conference call, please register in ...

Primary endpoint met in phase 2a POC trial in postpartum depression with a MADRS reduction from baseline of –35.4 points (p<0.0001, n=10) and 100% of patients in remission at Day 8Primary endpoint met in phase 2a POC trial in bipolar II disorder with a current major depressive episode with a MADRS reduction from baseline of –16.8 points (p=0.0099, n=6) and 33% of patients in remission at Day 8In both trials, GH001 was well tolerated and no treatment-related serious adverse events were reportedInhalation tox ...

GH Research PLC (GHRS) closed the last trading session at $9.61, gaining 15.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $31.25 indicates a 225.2% upside potential.The average comprises four short-term price targets ranging from a low of $18 to a high of $40, with a standard deviation of $10.37. While the lowest estimate indicates an increase of 87.3% from the current price l ...

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression completed enrolment of the double-blind phase in Q3 2024Phase 1 clinical trial to evaluate proprietary aerosol delivery device in healthy volunteers is ongoing in the UKCash, cash equivalents, other financial assets and marketable securities of $193.8 million DUBLIN, Nov. 14, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric ...

Comparing and selecting stocks for investment may involve any number of increasingly complex strategies and approaches, but sometimes simpler is better: targeting a stock with significant upside potential at an opportune moment. Certainly, achieving this goal is easier said than done, and there is no guarantee that a company expected to make sizable gains will follow through on that promise. However, looking to Wall Street analyst ratings and predictions can be a helpful place to start. In a screen of stock ...

GH Research PLC (GHRS) has been beaten down lately with too much selling pressure. While the stock has lost 18.2% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier. Guide to Identifying Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator ...